ArticleFrontiers in psychiatry2026
Clozapine-induced inflammation: a case report.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Clozapine is highly effective for treatment-resistant schizophrenia, schizoaffective disorder, and treatment-resistant mania. However, it is associated with significant inflammatory adverse effects, including fever and severe organ involvement such as myocarditis, pneumonia, and enteritis. Close serial monitoring of inflammatory markers (white blood cell count, C-reactive protein, and neutrophils) combined with individualized, slow dose titration is essential to minimize these risks. Case report: We describe a 21-year-old Chinese male with treatment-resistant mania who developed fever, pulmonary inflammation, myalgia, nausea, vomiting, abdominal distension, leukocytosis with neutrophilia, and elevated C-reactive protein during the initial rapid titration of clozapine. The inflammatory response resolved promptly after dose reduction and did not recur with a slower titration schedule and lower maintenance dose. Conclusions: This case highlights the importance of vigilant monitoring of inflammatory markers during clozapine initiation and supports the use of personalized titration regimens, particularly in East Asian populations who may be at heightened risk of clozapine-induced inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.